Press Releases

For Immediate Release
Date: February 29, 2008
Contact: Carlene Simmons, Marketing Communications Manager
Phone: 800.871.8909 ext. 109

FDA Clears Doripenem for TREK Sensititre® In Vitro Dry Microbroth Plates used in Clinical-Diagnostic Laboratories

Cleveland, Ohio — Februrary 29, 2008 – TREK Diagnostic Systems, a Magellan Biosciences company and leading provider of susceptibility products for microbiology labs, is the first diagnostic manufacturer of dry microbroth dilution plates to offer an in vitro diagnostic-labeled product to test Doripenem (DORIBAX™) in diagnostic laboratories. TREK products now have clearance to test and report Doripenem against Gram negative bacilli using Sensititre MIC susceptibility methods, enabling laboratories to report additional antimicrobic results and providing a wider range of treatment options for clinicians.

“We are pleased to announce the extension of our clearance claims for Doripenem, which was previously available to our customers for research use only,” commented the Director of Global Marketing for TREK Diagnostic Systems, Jenny Lorbach. “Diagnostic labs can now test and report the broadest range of antimicrobials using the Sensititre platform. We continue to offer new antimicrobials for in vitro diagnostic test methods earlier than manufacturers of other automated test methods – a key part of our commitment to help our laboratory customers deliver better results to improve health outcomes for patients.”

Doripenem was cleared by the FDA on October 12, 2007, for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. It belongs to the carbapenem class of antibacterial agents, which are useful in treating infections caused by Gram positive and Gram negative bacteria. Doripenem is manufactured in the U.S. by Johnson & Johnson Pharmaceutical Research and Development, L.L.C., and marketed under the name DORIBAX.

With a long history of developing and manufacturing cost-effective customized susceptibility and identification plates, TREK Diagnostic Systems offers a full range of services for clinical trial management worldwide, including custom susceptibility plate design, MIC testing for new drug clearance, resistance surveillance testing, antifungal testing, and frozen CLSI reference plate manufacturing. TREK provides full diagnostic support for laboratories in the United States and in Europe.

Founded in January 1999, TREK Diagnostic Systems is a global manufacturer and distributor of automated systems and consumable products for the microbiology diagnostic laboratory. Signature product lines include VersaTREK®, Sensititre®, alamarBlue®, para-JEM®, YeastOne®, onSite®, and TREK Lab Services. TREK is committed to delivering the highest-quality products and services to clinical, pharmaceutical, and veterinary diagnostic laboratories worldwide. TREK is a wholly owned subsidiary of Magellan Biosciences.

For more information, contact Carlene Simmons at 1.800.871.8909 ext. 109 or via e-mail at csimmons@trekds.com.